THE BIOCHEMISTRY OF RAPID REPLICATION

In the last decade, outbreaks of SARS, H5N1 (bird flu) and H1N1 (swine flu) have increased awareness of the need for rapid vaccine development in response to emerging viral threats. Replikins’ software-driven technology allows for earlier development of vaccine candidates, as well as rapid prototyping and production of the vaccines that emerge from early clinical trials.

Overview

more about us

OUR PRODUCTS

Replikins, Ltd. develops and markets novel forecasting tools and synthetic vaccines to fight virulent rapidly replicating diseases including bird flu, malaria, and HIV.

ADVANCE WARNING

To date, no means has been available to predict if and what strain of a given organism will threaten a human or animal population.

PREDICTIVE TOOLS

The company's vaccines and predictive tools are based on the company's discovery of a new group of peptides responsible for rapid replication called Replikins, whose increase in concentration in virus or other organism proteins (Replikin Count™ peptide quantities) is associated with rapid replication.

FLUFORECAST™

There is a clear need for better measures against both natural and man-made emerging epidemic threats. Our FluForecast™ product leverages the core Replikins technology to help identify rises in peptide quantities which precede observed epidemics by one to two years. Further, after an epidemic runs its course there is a decline in those quantities.

The United Nations FAO, among others, has identified the promise of this technology in driving appropriate public health measures, and in getting an early start on targeted vaccine development. Replikins believes that it can provide a clear competitive advantage to companies and governments in this area.

Interview

VIDEOS

FIELD RESULTS

In a December 2009 article in the journal Avian Diseases, a team led by Mark Jackwood of the University of Georgia reported a breakthrough use of a synthetic H5N1 vaccine developed by Replikins to inoculate chickens against the “bird flu”.

The vaccine was delivered via aerosol to the upper respiratory tract, and was found to confer significant protection against the highly infectious H5N1 virus. The abstract is online at BioOne with the full article available for a fee.

CONTACT US

Address:
Replikins, Ltd
38 the Fenway
Boston, MA 02215

Phone: (646) 320-5910
Fax: (617) 536-0657
Email: samuel.bogoch@replikins.com